Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Further validation of NitroMed's approach to new drug candidates for GI diseases

June 13, 2000

Hepatitis C virus NS3 helicase inhibitors designed at Vertex

June 8, 2000

Restricted access program for Prepulsid to be implemented in Canada

June 8, 2000

AxyS continues phase II study of tryptase inhibitor as ulcerative colitis treatment

June 6, 2000

BDNF reported to be useful for liver diseases

June 2, 2000

Alizyme acquires renzapride, receives equity investment from SmithKline Beecham

June 2, 2000

Dosmalfate launched in Spain for prophylaxis of gastric lesions and ulcers

June 1, 2000

Human Genome Sciences to begin phase II trials of repifermin in ulcerative colitis

June 1, 2000

PEG-Intron monotherapy approved for HCV in E.U.

May 31, 2000

Phase I/II data reported for Millennium's humanized alpha4beta7 antibody

May 31, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...